CN113825756A - 取代的多环羧酸、其类似物和其使用方法 - Google Patents

取代的多环羧酸、其类似物和其使用方法 Download PDF

Info

Publication number
CN113825756A
CN113825756A CN202080016321.4A CN202080016321A CN113825756A CN 113825756 A CN113825756 A CN 113825756A CN 202080016321 A CN202080016321 A CN 202080016321A CN 113825756 A CN113825756 A CN 113825756A
Authority
CN
China
Prior art keywords
butyl
tert
oxo
carboxylic acid
difluoromethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080016321.4A
Other languages
English (en)
Chinese (zh)
Inventor
陈帅
A·G·科尔
B·D·多尔西
范怡
D·B·哥彻夫
R·卡卡尔拉
S·M·柯克
J·昆特罗
M·J·索菲亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arbutus Biopharma Corp
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of CN113825756A publication Critical patent/CN113825756A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080016321.4A 2019-01-17 2020-01-15 取代的多环羧酸、其类似物和其使用方法 Pending CN113825756A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962793578P 2019-01-17 2019-01-17
US62/793,578 2019-01-17
PCT/US2020/013701 WO2020150366A1 (en) 2019-01-17 2020-01-15 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same

Publications (1)

Publication Number Publication Date
CN113825756A true CN113825756A (zh) 2021-12-21

Family

ID=71613992

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016321.4A Pending CN113825756A (zh) 2019-01-17 2020-01-15 取代的多环羧酸、其类似物和其使用方法

Country Status (15)

Country Link
US (1) US20220125771A1 (https=)
EP (1) EP3911653A4 (https=)
JP (1) JP2022518456A (https=)
KR (1) KR20210121044A (https=)
CN (1) CN113825756A (https=)
AU (1) AU2020208371A1 (https=)
BR (1) BR112021014079A2 (https=)
CA (1) CA3126102A1 (https=)
EA (1) EA202191967A1 (https=)
IL (1) IL284845A (https=)
MX (1) MX2021008646A (https=)
PH (1) PH12021551718A1 (https=)
SG (1) SG11202106965RA (https=)
TW (1) TW202033523A (https=)
WO (1) WO2020150366A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819200A (zh) * 2022-11-28 2023-03-21 辽宁科技学院 一种苊醌的合成方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10952978B2 (en) 2017-08-28 2021-03-23 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US11702427B2 (en) 2018-03-12 2023-07-18 Arbutus Biopharma Corporation Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
CN110862390B (zh) 2018-08-28 2023-05-09 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
UY38383A (es) 2018-09-21 2020-04-30 Enanta Pharm Inc Heterociclos funcionalizados como agentes antivirales
CA3111046A1 (en) 2018-09-30 2020-04-02 Sunshine Lake Pharma Co., Ltd. Fused tetracyclic compounds and uses thereof in medicine
US11198693B2 (en) 2018-11-21 2021-12-14 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) * 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202304914A (zh) * 2021-04-05 2023-02-01 加拿大商愛彼特生物製藥公司 經取代之四環羧酸、其類似物及使用其之方法
WO2024038357A1 (en) * 2022-08-16 2024-02-22 Arbutus Biopharma Corporation Synthesis of substituted tetracyclic carboxylic acids and analogues thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2018073753A1 (en) * 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
WO2018198079A1 (en) * 2017-04-27 2018-11-01 Novartis Ag Fused indazole pyridone compounds as antivirals

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (uk) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
JP6506880B2 (ja) * 2015-07-27 2019-04-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｂ型肝炎ウィルス感染症の治療および予防のための新規な四環式４−オキソ−ピリジン−３−カルボン酸誘導体
US20200270265A1 (en) * 2016-02-19 2020-08-27 Novartis Ag Tetracyclic pyridone compounds as antivirals
CN110066278B (zh) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
WO2018073753A1 (en) * 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
WO2018198079A1 (en) * 2017-04-27 2018-11-01 Novartis Ag Fused indazole pyridone compounds as antivirals

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASE, FRANCIS H等: "Substituted 1, 10-phenanthrolines. IX. Cycloalkeno derivatives", 《JOURNAL OF ORGANIC CHEMISTRY》, vol. 21, pages 1069 - 1071, XP055146378, DOI: 10.1021/jo01116a005 *
HE, SHUWEN等: "A general approach to access 5, 6-dihydroindolo-naphthyridine ring system", 《TETRAHEDRON LETTERS》, vol. 58, no. 14, pages 1373 - 1375, XP029942629, DOI: 10.1016/j.tetlet.2017.02.030 *
SAEKI, KEN-ICHI等: "Activation of the human Ah receptor by aza-polycyclic aromatic hydrocarbons and their halogenated derivatives", 《BIOLOGICAL & PHARMACEUTICAL BULLETIN》, vol. 26, no. 4, pages 448 - 452, XP055965148 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115819200A (zh) * 2022-11-28 2023-03-21 辽宁科技学院 一种苊醌的合成方法
CN115819200B (zh) * 2022-11-28 2023-08-29 辽宁科技学院 一种苊醌的合成方法

Also Published As

Publication number Publication date
EP3911653A1 (en) 2021-11-24
WO2020150366A1 (en) 2020-07-23
AU2020208371A1 (en) 2021-07-15
KR20210121044A (ko) 2021-10-07
EP3911653A4 (en) 2022-11-02
PH12021551718A1 (en) 2022-03-28
MX2021008646A (es) 2021-10-26
BR112021014079A2 (pt) 2021-09-21
SG11202106965RA (en) 2021-08-30
IL284845A (en) 2021-08-31
JP2022518456A (ja) 2022-03-15
CA3126102A1 (en) 2020-07-23
EA202191967A1 (ru) 2021-10-07
US20220125771A1 (en) 2022-04-28
TW202033523A (zh) 2020-09-16

Similar Documents

Publication Publication Date Title
CN113825756A (zh) 取代的多环羧酸、其类似物和其使用方法
CN110114071B (zh) 含有取代的吡啶酮的三环化合物以及使用其的方法
KR102705376B1 (ko) 화학적 화합물
TWI801517B (zh) 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
TWI815887B (zh) 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
KR20220088375A (ko) 피롤아미드 화합물 및 그 용도
TW202304914A (zh) 經取代之四環羧酸、其類似物及使用其之方法
KR20230011981A (ko) 치환된 트리사이클릭 아미드, 이의 유사체, 및 이를 사용하는 방법
TW202132285A (zh) 經取代異吲哚啉基2,2’-聯嘧啶基化合物、其類似物及使用其之方法
TW202138352A (zh) 經取代之雙環及三環脲類及醯胺類、其類似物及使用其之方法
TW202120495A (zh) 經取代環丙基—２，２＇—聯嘧啶基化合物、其類似物及其使用方法
HK40058308A (en) Substituted polycyclic carboxylic acids, analogues thereof, and methods using same
HK40012821B (en) Substituted pyridinone-containing tricyclic compounds, and methods using same
HK40012821A (en) Substituted pyridinone-containing tricyclic compounds, and methods using same
TW202430515A (zh) 經取代之1-芳基胺基羰基-1’-雜芳基化合物、經取代之1-雜芳基胺基羰基-1’-雜芳基化合物及其使用方法
TW202321255A (zh) 經取代之三環醯胺及其類似物的合成

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058308

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211221

WD01 Invention patent application deemed withdrawn after publication